Andrea Apolo

Andrea Apolo leads bladder cancer research at the NCI and has made significant contributions to the development of avelumab maintenance therapy in urothelial carcinoma. She was a principal investigator in the JAVELIN Bladder 100 trial that established avelumab as standard maintenance therapy after platinum chemotherapy. Her research program spans immunotherapy optimization, novel drug combinations, and tissue biomarker development in bladder and kidney cancers. She has been influential in defining maintenance immunotherapy as a new treatment paradigm in urothelial cancer.